SNTI · Senti Biosciences Holdings, Inc.
$0.23
+0.00 (+0.49%)
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We concluded that substantial doubt continued to exist and that our cash and cash equivalents of $6.5 million as of June 30, 2026, were not sufficient for us to continue as a going concern for at least one year from the issuance date of the condensed consolidated financial statements. Based on our current operating plan and existing unrestricted cash and cash equivalents, we have determined that we may not be able to maintain current operations starting as early as the fourth quarter of 2026. Additional funds will be necessary to maintain operations and to continue research and development activities. Our continued existence is dependent upon management's ability to raise capital, collect amounts owed to us under existing agreements and ultimately develop profitable operations. While management is devoting substantially all of its efforts to developing our business, raising capital and collecting amounts owed to us under existing agreements, there can be no assurance that our efforts will be successful.”View the 10-Q filed Aug 14, 2026
Market Cap
$7.06M
Shares
31.14M
Volume · Oct 20
248.3K
Avg daily vol (3M)
854.97K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.23
Open$0.22
Day$0.21–0.23
52W close$0.22–2.39
Avg vol 30d1.6M
Short int487K · 1.6% float · 1.0d
Short vol17%
Last earningsMay 14, 2026
DataMay 2021–Oct 2026
Filing10-Q · Aug 14
Up next
filed Aug 14, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$55,000
Trailing 12 months
Net income (TTM)
−$49.56M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
-312,631.8%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$6.46M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+19.4%
Year over year · more shares
Price change (1Y)
-89.5%
Trailing year
Short interest
1.6%
Latest settlement · 1.0 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 18.4 · elevated
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−70%
below
Price vs 50-day avg
−33%
below
RSI (14)
30
neutral
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−27%
trailing
6-month return
−76%
trailing
YTD return
−78%
this year
Relative strength
−84%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
+25% holders QoQ · +6 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.56% of float · ▼ -4.6% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
20 holders — mid 5-yr range
Squeeze score
38
low risk · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
+77%
Y/Y
Free cash flow
$-43.6M
Quant / Vol
risk profile
Volatility
100%
annualized · 1-yr
Max drawdown
−91%
past year
ATR
13.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−70%
Bearish
Price vs 50-day avg
−33%
Bearish
RSI (14)
30
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
+25% holders QoQ · +6 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.56% of float · ▼ -4.6% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
20 holders — mid 5-yr range
Price context
position in its 52-week range
Range low $0
Now $0 · 0%
Range high $2
vs 200-day avg -70%
vs 50-day avg -33%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SNTI
this stock
Senti Biosciences Holdings, Inc.
|
$7.06M | -78.2% | -100.0% | — | 1.6% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.07B | +10.7% | +46.2% | 29.9 | 1.8% |
|
MRNA
Moderna, Inc.
|
$90.58B | +669.4% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.51B | +1.3% | +20.8% | 19.4 | 2.1% |
|
CSLLY
Csl Ltd
|
$64.50B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
SEC Filings
Latest
8-K
- Filed
- Oct 15, 2026
- This year
- 29
Senti Biosciences Holdings, Inc. stockholders approved the July 14, 2026 merger, authorized issuance of more than 19.99% of common stock upon note exchange, and approved a reverse stock split ranging from 1-for-20 to 1-for-50.
ViewEarnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SNTI | -28.8% | -26.8% | -76.3% | -27.4% | -78.2% |
| SPY | -1.5% | -0.9% | +7.7% | +0.5% | +12.4% |
| vs SPY | -27.3% | -25.9% | -84.0% | -27.9% | -90.6% |